Industry Outlook

The CAR-T cell therapy market was valued at US$ 174.24 Mn in 2021 and projected to exhibit double digit compound annual growth rate (CAGR) of 35.5% during the forecast period from 2025 to 2033. Scientist have encountered the biggest challenge in the treatment of cancer is that the cancer cells with the disease progression usually become invisible to the body’s defense mechanism. Immunotherapy is the future in the treatment of cancer where the immune cells are genetically engineered in order to recognize the biomarkers of cancerous cells, target them and kill them. CAR-T cells therapy do not kill the normal healthy cells and has proven effective in relapsed cancer treatment. The CAR-T cell therapy market is driven by factors such as rising prevalence of cancer, growing research in the immune-oncology, and massive funding from government health institution and pharma giants in CAR-T cell therapy development. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. However, advances in the cell therapy and gene therapy has have rendered the development of oncology treatment by body’s own immune system. The FDA approved CAR-T cell therapy are Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. Whereas, there are more than 2,000 candidates in the clinical trials for different cancer indications.

Growing Research and Development of CAR-T to Drive the Market Growth

CD 19 antigens are currently studied extensively to prove its efficacy in the treatment of acute lymphoblastic leukemia. Rising prevalence of acute lymphoblastic leukemia in children and adults has buttressed the dominance of CD 19 antigens to be utilized for cancer therapy. Yescarta (axicabtagene ciloleucel), and Kymriah (tisagenlecleucel) are the two approved CD19 therapies and the only CAR-T cell therapies currently approved in the market. CD 22 and CD 30 antigens are being studied diligently in the preclinical trials with promising results for the treatment of B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma respectively.

Rising Prevalence of Blood Cancers to Augment the Growth of CAR-T Cell Therapy Market

The non-Hodgkin’s lymphoma segment dominated the market in 2021 owing to a surge in the number of NHL cases coupled with the higher adoption of YESCARTA (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel, formerly CTL019) around the world. CAR T cell therapy products are currently indicated in non-Hodgkin’s lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia only. However, clinical trials of some CAR T cell therapy drugs being studied (under study) for the treatment of multiple myeloma, acute myeloid leukemia, melanoma, glioblastomas, myelodysplastic syndromes (MDS), and cancer of pancreatitis, prostate, bladder, esophagus, stomach, liver, lung, kidney, & cervix. Thus, proliferating application of CAR-T in various indication would further boost the market during the forecast period.

Increasing Adoption of CAR-T Cell Therapy in North America will Drive Swift Growth during the Forecast Period

In 2021, North America demonstrates supremacy in the global CAR-T cell therapy market owing to the exclusive availability of the two approved products Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.). Developed healthcare infrastructure, high accessibility to advanced therapies, rise in healthcare expenditure, incessant investment in R&D activities, and presence of established market leaders further catalyzes the overall market growth in this region. With Medicare constantly working on structuring suitable reimbursement policies for dynamically priced CAR-T cell therapies, the demand for it is projected to increase during the forecast period. In Asia Pacific, the market entry of Kymriah expected by end of 2025 in Japan. The extensive pipeline portfolio for CAR-T cell therapy in China and the continuous growing cancer prevalence in Asia Pacific regions predominantly contribute to the maximum growth.

Market is studied in order to understand the current and future market trends in the CAR-T cell therapy market. The market is estimated by providing the compounded annual growth rate (CAGR) and data forecast from 2025 to 2033. Strategic acquisition, merger and collaboration among the key players for developing innovative product pipeline mentioned in the business strategy section. The key players currently engaged in the CAR-T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Juno Therapeutics, Cellectis, Eureka Therapeutics, Kite Pharma, Sorrento Therapeutics and Novartis AG, Gilead Sciences among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of CAR-T Cell Therapy market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the CAR-T Cell Therapy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of CAR-T Cell Therapy market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the CAR-T Cell Therapy market?
• Which is the largest regional market for CAR-T Cell Therapy market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving CAR-T Cell Therapy market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the CAR-T Cell Therapy market worldwide?